PTPRC and neoplasm: Flow cytometry analysis of splenic T cells from CT2A tumor–bearing mice demonstrated that treatment with cilengitide, AR-A014418, or WP1066 increased the populations of CD3+ (CD45+CD3+) and CD8+ (CD45+CD3+CD8+CD4–) T cells, but not CD4+ (CD45+CD3+CD4+CD8–) T cells (Supplemental Figure 8, B–D).